Last reviewed · How we verify

NCT00800358

A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

Completed NA Last updated 4 December 2012
What this trial tests

NA trial testing Paricalitol in Hyperparathyroidism in 69 participants. Completed in 1 December 2009.

Timeline
1 November 2008
Primary endpoint
1 October 2009
1 December 2009

Quick facts

Lead sponsorPenang Hospital, Malaysia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment69
Start date1 November 2008
Primary completion1 October 2009
Estimated completion1 December 2009
Sites11 locations across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

Penang Hospital, Malaysia

Who can join

18 and older, any sex, with Hyperparathyroidism or Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine whether oral paricalcitol is safer and more efficacious compared to oral calcitriol in the treatment of hyperparathyroidism in chronic kidney disease patients undergoing dialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyperparathyroidism

Currently open trials in the same condition.

Other Penang Hospital, Malaysia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00800358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing